List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 13 studies with search of: Open Studies | "Urethral Neoplasms"
Include studies that are not seeking new volunteers.
Hide studies with unknown recruitment status.
  Display Options
Rank Status Study
1 Recruiting Gemcitabine, Cisplatin, and Lenalidomide for Bladder Cancer
Conditions: Ureteral Neoplasms;   Urinary Bladder Neoplasms;   Urethral Neoplasms
Interventions: Drug: Lenalidomide;   Drug: Cisplatin;   Drug: Gemcitabine
2 Recruiting Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
Conditions: Urethral Neoplasms;   Neoplasms, Urethral;   Ureter Cancer;   Cancer of the Urethra;   Urethral Cancer
Interventions: Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Lenalidomide
3 Recruiting Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
Conditions: Solid Tumor;   Urethral Cancer
Interventions: Drug: Bortezomib;   Drug: Gemcitabine;   Drug: Doxorubicin
4 Recruiting Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Cancer;   Prostate Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
Interventions: Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: placebo administration
5 Unknown † Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer
Conditions: Bladder Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
Interventions: Drug: sunitinib malate;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: quality-of-life assessment
6 Recruiting E7389 in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
Conditions: Bladder Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
Interventions: Drug: eribulin mesylate;   Other: pharmacological study
7 Recruiting Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
Conditions: Carcinoma of Urinary Tract;   Urethral Carcinoma;   Carcinoma of Ureter;   Carcinoma of Renal Pelvis
Interventions: Drug: Docetaxel;   Biological: Ramucirumab DP;   Biological: IMC-18F1
8 Unknown † Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium
Conditions: Bladder Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
Interventions: Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: temsirolimus;   Other: pharmacological study
9 Recruiting A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Conditions: Transitional Cell Carcinoma of Bladder;   Urethra Cancer;   Ureter Cancer;   Malignant Tumor of Renal Pelvis
Interventions: Drug: Cisplatin;   Drug: Gemcitabine;   Biological: ALT-801
10 Recruiting Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment
Conditions: Bladder Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
Interventions: Drug: pazopanib hydrochloride;   Radiation: fludeoxyglucose F 18
11 Recruiting Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer
Conditions: Melanoma;   Merkel Cell Carcinoma;   Squamous Cell Carcinoma;   Penile Carcinoma;   Urethral Carcinoma;   Extramammary Paget's Disease;   Scrotal Carcinoma;   Anal Cancer;   Vulvar Cancer;   Skin Cancer;   Lymphadenopathy
Interventions: Procedure: Videoscopic procedure;   Procedure: Open, traditional approach
12 Recruiting Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium
Conditions: Bladder Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
Interventions: Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: sunitinib malate
13 Recruiting Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
Conditions: Bladder Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Ureter Cancer;   Urethral Cancer
Interventions: Drug: carboplatin;   Drug: gemcitabine hydrochloride;   Drug: vandetanib;   Drug: Placebo

† Indicates status has not been verified in more than two years
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services